Nigeria Set to Introduce Twice-Yearly HIV Prevention Injection

Nigeria is preparing to receive a new long‑acting HIV prevention medication called lenacapavir in March 2026. The injectable drug, which requires just two doses per year, is expected to provide a major boost to the country’s efforts to curb new HIV infections.

The medication will be offered as a form of pre‑exposure prophylaxis (PrEP), targeting individuals at higher risk of contracting HIV. Health authorities are working to ensure that the rollout reaches the communities that need it most, combining medical distribution with education and awareness campaigns.

Regulatory approval for the drug has already been secured, and preparations are underway to train healthcare workers on its proper administration. This step is seen as crucial to ensure the safe and effective delivery of the treatment across the country.

The introduction of lenacapavir is part of Nigeria’s broader strategy to strengthen HIV prevention, expand access to innovative healthcare tools, and reduce the number of new infections nationwide. Officials hope that this twice-yearly injectable option will make prevention more convenient and encourage more people to take proactive measures against HIV.